For decades, biologics have been the gold standard for psoriasis treatment. Now, the psoriasis therapeutic landscape is transforming with new medications that approach biologic-level efficacy in pill ...

HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application ...

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides ...

Biologic medications improve inflammation in Crohns disease by blocking immune system proteins that cause it. By doing this, these drugs decrease symptoms, lower your risk of flares, and help the ...

TREMFYA met the primary endpoint of combined fistula remission at Week 24, defined as complete closure of all external fistula openings with no drainage, without development of new fistulas and no ...

JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to ...

Information about medical eligibility, benefits, claims and referral information. To support OHSU Health IDS members transition from CareOregon providers, Health Share of Oregon is distributing a list ...

The Food and Drug Administration (FDA) approved Skyrizi to treat the following conditions in certain adults: Skyrizi is a brand-name biologic drug. It’s not available in biosimilar form. Biologic ...

Tremfya is used to treat irritable bowel disease (ulcerative colitis and Crohn’s disease) in adults. It’s also approved for plaque psoriasis and psoriatic arthritis in adults and some children.

Good day, and thank you for standing by. Welcome to the Option Care Health Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being ...

More than 80% of those treated with TREMFYA ® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease ...

The cost of Tremfya can vary depending on the form of the drug, your insurance coverage, and whether you receive injections at a doctor’s office or administer them yourself at home. Financial ...